Alternative treatments of adenomyosis - an update in procedural management and clinical outcomes

• Published in: Current opinion in obstetrics & gynecology Vol. 36; no. 4; p. 287
• Main Authors: Zeccola, Alison M, Allen, Sarah E
• Format: Journal Article
• Language: English
• Published: England 01.08.2024
• Subjects: Adenomyosis - therapy; Dysmenorrhea - etiology; Dysmenorrhea - therapy; Female; High-Intensity Focused Ultrasound Ablation; Humans; Pelvic Pain - etiology; Pelvic Pain - therapy; Radiofrequency Ablation - methods; Treatment Outcome; Uterine Artery Embolization; Uterine Hemorrhage - etiology; Uterine Hemorrhage - therapy
• ISSN: 1473-656X
• DOI: 10.1097/GCO.0000000000000972

Adenomyosis is a common cause of abnormal uterine bleeding (AUB), dysmenorrhea, and pelvic pain. Definitive diagnosis and treatment have historically been by uterine histopathology at time of hysterectomy; however, advances in imaging have supported earlier diagnosis and subsequent conservative treatment. This review aims to update the evidence supporting the uterine-sparing, procedural management options with a focus on clinical outcomes. Uterine artery embolization (UAE), radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), percutaneous microwave ablation (PMWA), and adenomyomectomy are minimally invasive interventions proven to be effective in reducing AUB and dysmenorrhea due to adenomyosis. Symptom improvement is associated with a decrease in uterine volume. Studies support the use of alternative treatment options given the overall low rates of symptom recurrence and reintervention. Combination therapy may be more effective than monotherapy. This review provides the current evidence for use of alternative treatment options for adenomyosis. Access to ablative therapies in the USA is limited and primarily off label, given lack of FDA approval. High-quality prospective and randomized controlled trials are needed in order to further delineate treatment comparisons, efficacy, safety, and ideal patient selection for these treatments. More data are needed to assess safety and utility in those desiring future fertility.